Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH MEROLA

Allopathic & Osteopathic Physicians Dermatology

NPI
1881807469
CMS profile
175866
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$174,109.23

265 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $63,152.91 62
UCB SA $20,631.99 35
GENZYME CORPORATION $18,041.52 7
Novartis Pharma AG $14,348.08 8
Celgene Corporation $11,016.34 40
ABBVIE INC. $10,189.69 32
PFIZER INC. $6,200.00 5
UCB, Inc. $5,742.04 9
Janssen Global Services, LLC $4,828.69 5
Amgen Inc. $4,647.73 17
LEO Pharma AS $4,455.93 29
EMD Serono, Inc. $3,800.00 2
Sun Pharmaceutical Industries Inc. $3,606.84 2
Janssen Biotech, Inc. $3,389.81 10
Lilly USA, LLC $30.40 1
SANOFI-AVENTIS U.S. LLC $27.26 1

Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH MEROLA

NPI 1881807469 · CMS profile ID 175866

Allopathic & Osteopathic Physicians / Dermatology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881807469?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH MEROLA, NPI 1881807469, CMS profile ID 175866. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881807469?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSEPH MEROLA, NPI 1881807469, CMS profile ID 175866. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881807469?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSEPH MEROLA, NPI 1881807469, CMS profile ID 175866, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881807469?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

265 matching records · $174,109.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 265 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 265.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $122.1806/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855259 CMS
Novartis Pharmaceuticals Corporation $53.0006/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855261 CMS
Novartis Pharmaceuticals Corporation $35.0006/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855263 CMS
Novartis Pharmaceuticals Corporation $585.0006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855243 CMS
Novartis Pharmaceuticals Corporation $24.9906/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855251 CMS
Novartis Pharmaceuticals Corporation $125.0006/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855265 CMS
UCB SA $6,000.0006/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637359 CMS
Novartis Pharma AG $367.1806/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692595671 CMS
Novartis Pharmaceuticals Corporation $66.4706/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855245 CMS
UCB, Inc. $67.3906/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688239313 CMS
UCB, Inc. $66.4306/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688239315 CMS
UCB, Inc. $211.5406/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688239305 CMS
UCB, Inc. $257.0006/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688239307 CMS
UCB, Inc. $66.3706/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688381093 CMS
AbbVie, Inc. $900.0006/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648225797 CMS
UCB SA $149.3306/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637251 CMS
UCB SA $20.6406/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637253 CMS
UCB SA $22.0206/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637255 CMS
UCB SA $24.7706/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637257 CMS
UCB SA $49.5506/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637259 CMS
UCB SA $49.5506/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637261 CMS
UCB SA $867.5105/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637165 CMS
UCB SA $158.3305/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681637139 CMS
UCB SA $13.4405/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681636401 CMS
UCB SA $15.3405/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681636403 CMS
UCB SA $15.2305/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681636405 CMS
UCB SA $3,600.0005/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681636407 CMS
Amgen Inc. $22.7405/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568193 CMS
Amgen Inc. $3.9405/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568198 CMS
Amgen Inc. $129.6405/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568203 CMS
Amgen Inc. $2.8605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568221 CMS
Janssen Biotech, Inc. $249.0105/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658593805 CMS
Janssen Biotech, Inc. $4.5605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658593809 CMS
UCB SA $33.4905/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635935 CMS
UCB SA $4.2205/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635937 CMS
UCB SA $5.8105/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635939 CMS
Novartis Pharmaceuticals Corporation $109.0604/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855267 CMS
Amgen Inc. $94.7704/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568183 CMS
Amgen Inc. $20.1204/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568187 CMS
AbbVie, Inc. $26.1004/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648225785 CMS
Novartis Pharmaceuticals Corporation $60.0204/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855295 CMS
Amgen Inc. $12.0704/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662568217 CMS
Janssen Biotech, Inc. $4.5604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658593799 CMS
Janssen Biotech, Inc. $14.6604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658593803 CMS
UCB SA $13.5604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635535 CMS
UCB SA $4.2204/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635537 CMS
UCB SA $47.7504/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681635539 CMS
ABBVIE INC. $15.3903/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943047831 CMS
ABBVIE INC. $22.5403/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943047835 CMS
ABBVIE INC. $2,457.6903/27/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943047837 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $174,109.23 265
PY2020 $175,277.82 68
PY2021 $162,133.83 74
PY2022 $169,332.69 150
PY2023 $181,413.58 171
PY2024 $142,887.72 228
PY2025 $157,372.26 155

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,309.99 4
PY2025 Principal investigator $89,079.81 6
PY2024 Recipient $11,721.21 2
PY2024 Principal investigator $49,789.01 6
PY2023 Recipient $52,601.88 8
PY2023 Principal investigator $40,911.85 8
PY2022 Recipient $51,228.38 38
PY2022 Principal investigator $109,554.53 6
PY2021 Recipient $72,258.10 52
PY2021 Principal investigator $184,555.27 21
PY2020 Recipient $64,755.03 40
PY2020 Principal investigator $292,838.60 33
PY2019 Recipient $15,355.69 12
PY2019 Principal investigator $144,340.21 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Novartis Pharmaceuticals Corporation $2,168.50 12/22/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291614
Principal investigator 1 Janssen Research & Development, LLC $25,564.00 11/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175409655
Principal investigator 1 UCB SA $2.25 10/27/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658024
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,550.42 10/03/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190314165
Recipient Novartis Pharmaceuticals Corporation $960.67 09/17/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292690
Recipient Novartis Pharmaceuticals Corporation $396.11 05/07/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292694
Recipient Amgen Inc. $7,784.71 03/12/2025 Covered Recipient Physician A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD No dispute reported 06/30/2026 1246637262
Principal investigator 1 UCB SA $1,051.14 01/31/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658286
Principal investigator 1 AstraZeneca UK Limited $28,628.00 01/27/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185538332
Principal investigator 1 UCB SA $31,284.00 01/23/2025 Non-covered Recipient Entity
The University Of Texas Southwestern Medical Center
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657370